M&A Update – Nov 17

– SEE to be acquired by CD&R for $42.15 cash per share, 15.9% premium, $10.3 billion
– RPTX to be acquired by XenoTherapeutics for an estimated $1.82 cash per share + CVR, 10.3% premium, $78.2 million
– PVBC / NBBK deal closed
– SRDX / GTCR announced FTC will not appeal denial of injunction
– AVDL determined Lundbeck proposal is superior, triggered a five business day matching period
– HOUS / COMP filed S-4. filed HSR Oct 31, closing H2 2026
– NVA.to / OVV.to filed Competition Canada Nov 7
– KEC.to / Cygnet Energy (NGP / Carlyle / ARC) filed Competition Canada Nov 4
– GCG/a.to / Desjardins Group cleared Competition Canada
– NSC shareholders approved UNP merger, closing early 2027
– SRDX TRO expires